



December 22, 2014

ImmunoGen, Inc. Appoints Richard J. Gregory, Ph.D. as EVP, Chief Scientific Officer; John M. Lambert, Ph.D. Named EVP, Distinguished Research Fellow

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Richard J. Gregory, Ph.D., as Executive Vice President, Research and Chief Scientific Officer (CSO), reporting to ImmunoGen President and CEO, Daniel Junius. Dr. Gregory will join the Company on January 5, 2015, at which time current CSO, John Lambert, Ph.D., will assume the position of Executive Vice President, Distinguished Research Fellow. Dr. Gregory brings to ImmunoGen deep scientific and research management experience, most recently serving as senior vice president and head of research for the Sanofi Genzyme Research & Development Center.

"Rich is a highly regarded leader who has extensive experience managing effective biotechnology research," commented Mr. Junius. "I am excited that he will be leading our research programs in support of bringing to patients effective new anticancer therapies and continued expansion of our technology portfolio and expertise."

Dr. Gregory has over twenty-five years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme. In 2003, he was appointed the head of research at Genzyme, with responsibility for early research - from discovery to development - for all Genzyme therapeutic areas, including an ADC initiative. Following Sanofi's acquisition of Genzyme in 2011, Dr. Gregory was appointed head of the Sanofi-Genzyme R&D Center and in that capacity was responsible for Genzyme R&D from discovery through regulatory approval.

During his tenure at Genzyme, a Sanofi Company, Dr. Gregory's teams made critical contributions to the successful development and recent approval of several products, including a groundbreaking oral therapy for Gaucher's disease and a new treatment option for patients with active multiple sclerosis. He received his doctorate in biochemistry from the University of Massachusetts at Amherst, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology. Dr. Gregory is the co-author of over 60 peer-reviewed publications and has 23 issued U.S. patents.

Dr. Gregory succeeds Dr. Lambert, who joined ImmunoGen in 1987 and has been the Company's CSO since 2008. Dr. Lambert assumes the newly created role of Executive Vice President, Distinguished Research Fellow and remains a member of ImmunoGen's executive team, reporting to Mr. Junius.

Mr. Junius noted, "John has played a key role in bringing ImmunoGen to where it is today, with a validated technology that is making a difference for patients with cancer. We are grateful that he will remain very much involved with the Company - contributing his scientific expertise - as part of the succession plan for our research organization."

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla[®]. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in clinical testing through the Company's partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla[®] is a registered trademark of Genentech, a member of the Roche Group.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

or
For Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.

News Provided by Acquire Media